Table 2.
Frequency of E138A and Transmitted Drug Resistance
| Belgium (n = 715) | Portugal (n = 3,916) | |||||
|---|---|---|---|---|---|---|
| E138A (%) | E138A (%) | |||||
| Subtype | TDR (%) | WT | TDR | TDR (%) | WT | TDR |
| All | 9.9 | 3.3 | 1.4 | 8.4 | 3.0 | 4.9 |
| A1 | 1.8 | 1.8 | 0 | 3.6 | 3.8 | 0.0 |
| B | 14.5 | 4.3 | 1.7 | 10.9 | 2.8 | 0.6 |
| C | 3.8 | 5.2 | 0.0 | 6.0 | 11.7 | 37.5 |
| F1 | 5.3 | 0.0 | 0.0 | 5.3 | 7.5 | 0.0 |
| G | 6.3 | 0.0 | 0.0 | 6.9 | 1.3 | 8.8 |
| AE | 3.9 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| AG | 4.6 | 0.0 | 0.0 | 7.1 | 2.1 | 3.9 |
The frequency of TDR and of RPV-RAM E138A in patients with (TDR) or without SDRMs (WT), according to subtype and geographical origin of the patient (Belgium–Leuven Cohort, Portugal, Portuguese Cohort).
SDRM, surveillance drug resistance mutation; TDR, transmitted HIV-1 drug resistance; WT, wild-type.